Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/18/2025

Indications for High-Intensity Statin Therapy

Primary Indications for High-Intensity Statins

  • The American College of Cardiology recommends high-intensity statins for patients with established atherosclerotic cardiovascular disease (ASCVD), as they reduce LDL-C by ≥50% and significantly decrease cardiovascular events 1, 2, 3
  • High-intensity statins are indicated for secondary prevention in adults ≤75 years with clinical ASCVD, reducing ASCVD events more than moderate-intensity therapy in these patients 1, 2, 3
  • The American College of Cardiology recommends high-intensity statins for primary prevention in patients with LDL-C ≥190 mg/dL (severe hypercholesterolemia) 2
  • Patients with diabetes aged 40-75 years with additional ASCVD risk factors should be considered for high-intensity statins 1

Specific High-Intensity Statin Options

  • Atorvastatin 40-80 mg daily reduces LDL-C by approximately 50% 1, 2
  • Rosuvastatin 20-40 mg daily reduces LDL-C by approximately 50-55% 1, 2

Special Populations and Considerations

  • The American Diabetes Association recommends high-intensity statins for patients with diabetes who have established ASCVD 1
  • For patients with chronic kidney disease (CKD) and eGFR <60 mL/min/1.73 m², dose adjustments may be needed, with a maximum of 10 mg daily for rosuvastatin and 20 mg daily for atorvastatin 4
  • For adults >75 years with ASCVD, moderate-intensity statins are generally preferred, but high-intensity statins can be considered based on risk-benefit assessment 2, 3

Clinical Outcomes

  • High-intensity statins significantly reduce cardiovascular events in patients with established ASCVD 2, 3
  • If patients cannot tolerate high-intensity statins, the maximally tolerated statin dose should be used, according to the American College of Cardiology 1, 2
  • Monitor for adverse effects, particularly myopathy, with high-intensity statins, as recommended by the American College of Cardiology 2, 3